M&R Capital Management’s Medifast MED Stock Holding History

M&R Capital Management’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14	Closed	-$520	–	553
2024 Q1	$520	Hold	14	–	–	﹤0.01%	533
2023 Q4	$912	Buy	14 +1	+8%	+$70	﹤0.01%	609
2023 Q3	$1K	Hold	13	–	–	﹤0.01%	587
2023 Q2	$1.23K	Hold	13	–	–	﹤0.01%	582
2023 Q1	$1.37K	Buy	13 +4	+44%	+$443	﹤0.01%	568
2022 Q4	$1.05K	Buy	+9	New	+$1.05K	﹤0.01%	566

Other funds holding MED

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

M&R Capital Management's MED Position: Q2 2024 in Review

M&R Capital Management sold out of Medifast (MED) in Q2 2024, closing a stake of 14 shares — an estimated $520 sold.

M&R Capital Management first reported a position in MED in Q4 2022 and held it in 6 quarters. The position peaked at $1.37K in Q1 2023. 158 funds tracked by Wall St. Rank hold MED as of Q2 2024.

M&R Capital Management reported no remaining Medifast position as of Q2 2024 after selling out during the quarter.
M&R Capital Management sold 14 Medifast shares in Q2 2024, an estimated $520.
M&R Capital Management first reported a position in Medifast in Q4 2022 and held it in 6 quarters.
M&R Capital Management's Medifast position peaked at $1.37K in Q1 2023.
158 funds tracked by Wall St. Rank held Medifast as of Q2 2024.

Based on M&R Capital Management's 13F filing for Q2 2024, filed 2 Jul 2024.